Nephrologists should embrace the holistic CKM approach to chronic disease and be part of the ongoing metabolic revolution by thinking beyond T2DM and becoming familiar with the beneficial effects of GLP-1 RAs on CVD and CKD risk in patients with overweight/obesity independent of the presence of T2DM or CKD
This synergistic mechanism enhances insulin secretion, reduces appetite, and improves metabolic flexibility
The side effects and the benefits come from the exact same mechanism
Payers should provide claims analyses of the cost of long-term care associated with obesity and related comorbidities relative to the current price tag of GLP-1s for the employers covered population to validate the preemptive savings an employer would achieve by opting to cover GLP-1s
MedBound Hub GLP-1 Drugs: Fighting Diabetes and Weight Gain General Madhumathi.N.Lambi December 25, 2025, 1:49pm 1 GLP-1 Drugs: Fighting Diabetes and Weight In recent years, GLP-1 receptor agonists have transformed the treatment landscape for type 2 diabetes and obesity, blurring the line between metabolic disease management and weight-loss therapy
10.1186/s12967-023-04166-8 155 YangF.YanS.HeY.WangF.SongS.GuoY.et al (2008)
